Revenue for Q1 rose 11% to $53.6m for AMRI. Discovery, development and small-scale manufacturing saw strong growth, but large-scale manufacturing saw a sales decline. In addition, AMRI has completes its new state-of-the-art 150m2 non-GMP High Potency development laboratory suite at its Albany, NY, facility.
AMRI
Tuesday 6 May 2008
AMRI sees sales rise, completes high potency facility
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment